教室紹介、スタッフ紹介、研究、業績等、順天堂大学大学院 免疫病・がん先端治療学講座に関する様々な情報をご案内します。

順天堂大学大学院 各研究分野紹介 免疫病・がん先端治療学
大学院医学研究科各研究分野紹介一覧免疫病・がん先端治療学講座 各研究分野紹介一覧へ

業績


 

2021

  【原著論文】
  1. Itoh T, Hatano R , Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Matsuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K.
    IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
    Cell Death Dis. 2021;12:520.
  2. Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C.
    Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
    Biomark Res. 2021;9:21.
 

2020

  【原著論文】
  1. Corridoni D, Antanaviciute A, Gupta T, Fawkner-Corbett D, Aulicino A, Jagielowicz M, Parikh K, Repapi E, Taylor S, Ishikawa D, Hatano R, Yamada T, Xin W, Slawinki H, Bowden R, Napolitani G, Brain O, Morimoto C, Koohy H, Simmons A.
    Single-cell atlas of colonic CD8+ T-cells in ulcerative colitis.
    Nat Med. 2020;26:1480-1490..
【特許】
  1. 森本幾夫大沼圭、波多野良、伊藤匠、金子有太郎
    抗癌剤への抵抗性改善剤
    出願日:2020年 6月 8日 出願番号:特願2020-099449
 

2019

  【原著論文】
  1. Sato T, Tatekoshi A, Takada K, Iyama S, Kamihara Y, Jawaid P, Rehman MU, Noguchi K, Kondo T, Kajikawa S, Arita K, Wada A, Murakami J, Arai M, Yasuda I, Dang NH, Hatano R, Iwao N, Ohnuma K, Morimoto C.
    DPP8 is a novel therapeutic target for multiple myeloma.
    Sci Rep. 2019;9:18094.
  2. Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K.
    Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
    Lung Cancer. 2019;137:64-70.
  3. Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T.
    Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.
    Cancers (Basel). 2019;11. pii:E1138.
  4. Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S, Aune TM, Dang NH, Kuwahara-Arai K, Ohnuma K, Morimoto C.
    Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.
    MAbs. 2019;11:1428-1442.
  5. Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, Narita Y, Iwata S, Yamazaki H, Matsuoka S, Dang NH, Ohnuma K, Morimoto C.
    Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
    PLoS One. 2019;14:e0218330.
  6. Mezawa Y, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Morimoto C, Hino O, Orimo A.
    CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers.
    Cancer Med. 2019;8:3936-3948.
  7. Santos MF, Rappa G, Karbanova J, Vanier C, Morimoto C, Corbeil D, Lorico A.
    Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins.
    J Cell Mol Med. 2019;23:4408-4421.
  8. Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, Takamori K, Morimoto C, Ohnuma K.
    Biological effects of IL-26 on T cell-mediated skin inflammation including psoriasis.
    J Invest Dermatol. 2019;139:878-889.
【総説】
  1. Ohnuma K, Hatano R, Dang NH, Morimoto C.
    Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
    Mod Rheumatol. 2019;29:721-732.
【著書】
  1. Okamoto T, Hatano R, Nakano K, Yamada T, Yamazaki H, Kaneko Y, Dang NH, Morimoto C, Ohnuma K. Regulation of proliferation of malignant mesothelioma cells by CD26-cyclophilin A molecular complex.
    In: Advances in Medicine and Biology. 2019;156:165-185.
    Ed Berhardt LV. Nova Science Publishers Inc., Hauppauge, NY.
【特許】
  1. 大沼圭森本幾夫、波多野良
    免疫チェックポイント阻害剤
    出願日:2019年1月15日 出願番号:特願2019-004480
 

2018

  【原著論文】
  1. Ikeda T, Kobayashi S, Morimoto C.
    Effects of repetitive transcranial magnetic stimulation on ER stress-related genes and glutamate, γ-aminobutyric acid and glycine transporter genes in mouse brain.
    Biochem Biophys Rep. 2018;17:10-16.
  2. Nishida H, Hayashi M, Morimoto C, Sakamoto M, Yamada T.
    CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.
    Blood Cancer J. 2018;8:99.
  3. Okamoto T, Yamazaki H, Hatano R, Yamada T, Kaneko Y, Xu CW, Dang NH, Ohnuma K, Morimoto C. Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.
    Biochem Biophys Res Commun. 2018;504:491-498.
  4. Ikeda T, Kobayashi S, Morimoto C.
    Gene expression microarray data from mouse CBS treated with rTMS for 30 days, mouse cerebrum and CBS treated with rTMS for 40 days.
    Data Brief. 2018;17:1078-1081.
【総説】
  1. Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C.
    A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target in selected immune disorders and cancers.
    Front Biosci. 2018;23:1754-1779.
【著書】
  1. Hatano R, Ohnuma K, Yamada T, Okamoto T, Komiya E, Otsuka H, Itoh T, Yamazaki H, Iwao N, Kaneko Y, Dang NH, Morimoto C .
    The use of the humanized anti-CD26 monoclonal antibody YS110 as a novel targeted therapy for refractory canceres and immune disrders.
    In:Advances in Medicine and Biology. 2018;129:1-44.
    Ed Berhardt LV. Nova Science Publishers Inc., Hauppauge, NY.
【特許】
  1. 森本幾夫 、波多野良、山田健人、大沼圭
    抗ヒト化CD26モノクローナル抗体
    出願日:2018年3月16日 出願番号:特願2018-049308
 

2017

  【原著論文】
  1. Ikeda T, Kobayashi S, Morimoto C .
    Gene expression microarray data from mouse cerebrum treated with rTMS for 30 days.
    Data Brief. 2017;15:948-969.
  2. Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, Indig FE, Basu SK, Ohnuma K, Morimoto C , Johnson PF, Biragyn A, Abdelmohsen K, Gorospe M.
    Identification of senescent cell surface targetable protein DDP4.
    Genes Dev. 2017;31:1529-1534.
  3. Komiya E, Hatano R, Otsuka H, Itoh T, Yamazaki H, Yamada T, Dang NH, Tominaga M, Suga Y, Kimura U, Takamori K, Morimoto C , Ohnuma K.
    A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus.
    J Dermatol Sci. 2017;86:212-221.
  4. Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C .
    First-in-Human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
    Br J Cancer. 2017;116:1126-1134.
【総説】
  1. Doonan BP, Ohnuma K, Dang LH, Morimoto C , Dang NH.
    Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target.
    Current Cancer Therapy Reviews. 2017;13:76-88.
【著書】
  1. Ohnuma K, Hatano R, Yamazaki H, Kaneko Y, Dang NH, Morimoto C .
    CD26-targeted therapy: a new horizon in malignant pleural mesothelioma management.
    In:Horizons in Cancer Research. 2017;64:129-162.
    Ed Watanabe HS. Nova Science Publishers Inc., Hauppauge, NY.
【特許】
  1. 森本幾夫 、波多野良、大沼圭、伊藤匠
    抗ヒトIL-26抗体
    出願日:2017年12月1日 出願番号:特願2017-231439
 

2016

  【原著論文】
  1. Ikeda T, Fragiadaki M, Shi-Wen X, Ponticos M, Khan K, Denton C, Garcia P, Bou-Gharios G, Yamakawa A, Morimoto C , Abraham D.
    Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections.
    Data Brief. 2016;8:1377-80.
  2. Ikeda T, Fragiadaki M, Shi-Wen X, Ponticos M, Khan K, Denton C, Garcia P, Bou-Gharios G, Yamakawa A, Morimoto C , Abraham D.
    Transforming growth factor-β-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts.
    Biochem Biophys Rep. 2016;7:246-252.
  3. Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C , Hino O.
    Establishment of anti-mesothelioma monoclonal antibodies.
    BMC Res Notes. 2016;9:324.
  4. Omata Y, Nakamura S, Koyama T, Yasui T, Hirose J, Izawa N, Matsumoto T, Imai Y, Seo S, Kurokawa M, Tsutsumi S, Kadono Y, Morimoto C , Aburatani H, Miyamoto T, Tanaka S.
    Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-induced Osteoclastogenesis by Comprehensive Analysis.
    PLos One. 2016;11:e0157992.
  5. Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yamada T.
    A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition.
    Cancer Cell Int. 2016;16:35.
  6. Nomura S, Iwata S, Hatano R, Komiya E, Dang NH, Iwao N, Ohnuma K, Morimoto C .
    Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains.
    Biochem Biophys Res Commun. 2016;474:111-117.
【総説】
  1. Ohnuma K, Hatano R, Itoh T, Iwao N, Dang NH, Morimoto C.
    Role of IL-26+CD26+CD4 T cells in pulmonary chronic graft-versus-host disease and treatment with caveolin-1-Ig Fc conjugate.
    Crit Rev Immunol. 2016;36:239-267.
  2. Morimoto C, Ohnuma K.
    [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule].
    Gan To Kagaku Ryoho. 2016;43:855-62.
 

2015

  【原著論文】
  1. Katayose T, Iwata S, Oyaizu N, Hosono O, Yamada T, Dang NH, Hatano R, Tanaka H, Ohnuma K, Morimoto C.
    The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.
    Biochem Biophys Res Commun. 2015;460:1069-75.
  2. Otsuki N, Iwata S, Yamada T, Hosono O, Dang NH, Hatano R, Ohnuma K, Morimoto C .
    Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I.
    Mod Rheumatol. 2015;25:562-70.
  3. Ohnuma K, Hatano R, Aune TM, Otsuka H, Iwata S, Dang NH, Yamada T, Morimoto C .
    Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.
    J Immunol. 2015;194:3697-712.
  4. Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, Dang NH, Okumura K, Morimoto C .
    CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway.
    J Immunol. 2015;194:960-72.
  5. Ohnuma K, Saito T, Hatano R, Hosono O, Iwata S, Dang NH, Ninomiya H, Morimoto C .
    Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.
    J Clin Lab Anal. 2015;29:106-11.
【総説】
  1. Ohnuma K, Hatano R, Morimoto C .
    DPP4 in anti-tumor immunity: going beyond the enzyme.
    Nat Immunol. 2015;16:791-2.
【特許】
  1. 山田健人,林睦、山田幸司、森本幾夫 、岡本俊博、金子有太郎
    抗CD26抗体と他の抗がん剤とを組み合わせた癌治療用組成物
    出願日:2015年9月11日 出願番号:特願2015-179672
 

2014

  【原著論文】
  1. Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T, Morimoto C .
    Clinical significance of soluble CD26 in malignant pleural mesothelioma.
    PLoS One. 2014;9:e115647.
  2. Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, Yamada T.
    Blockade of CD26 signaling inhibits human osteoclast development.
    J Bone Miner Res. 2014;29:2439-55.
  3. Komiya E, Ohnuma K, Yamazaki H, Hatano R, Iwata S, Okamoto T, Dang NH, Yamada T, Morimoto C .
    CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
    Biochem Biophys Res Commun. 2014;447:609-15.
  4. Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C .
    Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
    Br J Cancer. 2014;110:2232-45.
  5. Kwan JC, Liu Y, Ratnayake R, Hatano R, Kuribara A, Morimoto C, Ohnuma K, Paul VJ, Ye T, Luesch H.
    Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation.
    Chembiochem. 2014;15:799-804.
  6. Hatano R, Yamada T, Matsuoka S, Iwata S, Yamazaki H, Komiya E, Okamoto T, Dang NH, Ohnuma K, Morimoto C .
    Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
    Diagn Pathol. 2014;9:30.
  7. Okamoto T, Iwata S, Yamazaki H, Hatano R, Komiya E, Dang NH, Ohnuma K, Morimoto C .
    CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells.
    PLoS One. 2014;9:e86671.
 

2013

  【原著論文】
  1. Havre PA, Dang LH, Ohnuma K, Iwata S, Morimoto C, Dang NH.
    CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
    BMC Cancer. 2013;13:517.
  2. Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch BJ, Morimoto C .
    Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
    J Virol. 2013;87:13892-9.
  3. Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H, Morimoto C .
    Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
    Diabetes Res Clin Pract. 2013;102:e8-e12.
  4. Tao X, Hill TE, Morimoto C , Peters CJ, Ksiazek TG, Tseng CT.
    Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells.
    J Virol. 2013;87:9953-8.
  5. Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C .
    Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
    Br J Haematol. 2013;162:263-77.
  6. Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C , Yamada T.
    Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
    PLoS One. 2013;8:e62304.
  7. Ikeda T, Kurosawa M, Morimoto C , Kitayama S, Nukina N.
    Multiple effects of repetitive transcranial magnetic stimulation on neuropsychiatric disorders.
    Biochem Biophys Res Commun. 2013;436:121-7.
  8. Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C , Inai K.
    CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.
    Oncol Rep. 2013;29:21-8.
  9. Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C.
    CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.
    Immunology. 2013;138:165-72.
【総説】
  1. Ohnuma K, Morimoto C .
    DPP4 (dipeptidyl-peptidase 4).
    Atlas Genet Cytogenet Oncol Haematol. 2013;17:301-12.
【特許】
  1. 森本幾夫 大沼圭
    MERSコロナウイルス感染予防治療剤
    出願日:2013年9月17日 出願番号:特願2013-187124
  2. 森本幾夫 、波多野良、山田健人、大沼圭
    抗ヒトCD26モノクローナル抗体又はその抗原結合性断片
    出願日:2013年7月31日 出願番号:特願2013-158533
 

2012

  【原著論文】
  1. Yoshikawa N, Shimizu N, Maruyama T, Sano M, Matsuhashi T, Fukuda K, Kataoka M, Satoh T, Ojima H, Sawai T, Morimoto C , Kuribara A, Hosono O, Tanaka H.
    Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice.
    PLoS One. 2012;7:e52522.
  2. Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C .
    Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Clin Cancer Res. 2012;18:6326-38.
  3. Yamazaki H, Naito M, Ghani FI, Dang NH, Iwata S, Morimoto C.
    Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
    Biochem Biophys Res Commun. 2012;419:529-36.
  4. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C .
    CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
    Clin Cancer Res. 2012;18:1447-56.
【総説】
  1. Ohnuma K, Morimoto C .
    [CD26 and its signaling pathway].
    Nihon Rinsho. 2012;70 Suppl 8:176-80.
  2. Morimoto C, Ohnuma K.
    [Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
    Nihon Rinsho. 2012;70:2177-82.
 
Copyright © 2005 JUNTENDO All Rights Reserved.